An ever-evolving landscape: an update on the rapidly changing regulation and reimbursement of biosimilars in Canada.
GaBI Journal |
Since the introduction of the first infliximab biosimilar, Inflectra®, significant changes have been introduced in the Canadian biosimilar landscape, and both the regulatory and the reimbursement processes have been streamlined. Select changes have been instituted to ensure the sustainability of the Canadian healthcare system, promoting faster and greater uptake of the lower-cost biosimilars. As a result, these changes ensure that high quality biological treatments remain accessible to patients. Further, attitudes of Canadian physicians and patients have shifted towards the acceptance of biosimilars.
Eric CK Siu, Anne Tomalin, Kevin West, Sandra Anderson and George Wyatt collaborate to provide an update on the current status of biosimilars in the context of the Canadian market.